Condition (MeSH)
Thromboinflammation
ClinicalTrials.gov lists 9 trials for Thromboinflammation or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
9 of the 9 trials are tagged with Thromboinflammation itself; the rest are tagged with a narrower condition beneath it.
When did Thromboinflammation trials start? (4)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 1 |
| 2023 | 2 |
| 2020 | 1 |
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 9 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Thromboinflammation trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Not applicable | 2 |
| Observational | 4 |
How many Thromboinflammation trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Terminated | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Thromboinflammation? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. | Science (New York, N.Y.) | 2024 | Yes |
| Thromboinflammation is associated with clinical outcome after ST-elevation myocardial infarction. | Blood advances | 2024 | Yes |
| Isoquercetin for thromboinflammation in sickle cell disease: a randomized double-blind placebo-controlled trial. | Blood advances | 2024 | No |
| Immunothrombosis and Complement Activation Contribute to Disease Severity and Adverse Outcome in COVID-19. | Journal of innate immunity | 2023 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.